Based on my research, I can see that Pharvaris is scheduled to report Q3 2026 earnings around November 11-12, 2026. The key upcoming catalyst is the anticipated CHAPTER-3 pivotal trial data (for prophylaxis treatment) expected in Q3 2026 - which may or may not have been released yet given we're on November 10. The company also has an FDA PDUFA decision date set for April 2027 for its on-demand treatment. The stock is down over 11% in the last 30 days, and the company missed its last earnings expectations.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Pharvaris typically reports earnings before the market opens, meaning Day 0 reflects anticipation as the market closes before results are released, while Day +1 captures the first full trading session where investors react to the actual numbers.

Pharvaris has shown significant volatility around earnings releases, with an average absolute move of 4.27% on Day 0 and 4.20% on Day +1. The Day 0 range averages 6.75%, while Day +1 sees an even wider average range of 8.63%, indicating that the stock often experiences substantial intraday swings following results.

The most recent earnings release on August 12, 2026 produced the largest moves in the dataset, with the stock jumping 5.93% on Day 0 within a 10.59% range, then reversing to fall 6.64% on Day +1 within an 8.61% range. This pattern of initial enthusiasm followed by profit-taking has appeared multiple times in the company's history.

Looking at directional patterns, the stock has moved higher on Day 0 in five of the eight most recent reports, but Day +1 has been more mixed, with three positive and five negative sessions. The November 2025 earnings saw a 7.01% Day 0 gain followed by a 6.01% Day +1 decline, while April 2025 produced a sharp 7.49% Day 0 drop and an even steeper 10.45% Day +1 decline.

Investors should expect meaningful price movement around this release, with historical data suggesting a potential swing in the 4-7% range, though individual reports have produced moves well above this average. The wide intraday ranges indicate active trading and position adjustments as investors digest the results and management commentary.

Part 3: What Analysts Are Saying

Analyst Consensus and Price Targets

Pharvaris enjoys strong bullish sentiment from the analyst community, with a consensus rating of 4.79 out of 5.0—firmly in Strong Buy territory. The current coverage includes 12 Strong Buy ratings, 1 Moderate Buy, and 1 Hold, with zero Sell or Strong Sell ratings among the 14 analysts covering the stock.

The average price target stands at $59.85, implying 76% upside from the current price of $33.99. Price targets range from a low of $42.00 to a high of $79.00, with even the most conservative target suggesting meaningful appreciation potential.

Improving Sentiment Trend

Analyst sentiment has improved over the past month, with the number of Strong Buy ratings increasing from 11 to 12, while Hold ratings declined from 2 to 1. The average recommendation strengthened from 4.64 to 4.79, reflecting growing confidence following the successful CHAPTER-3 Phase 3 readout in September and the FDA's acceptance of the NDA for deucrictibant immediate-release.

This positive shift comes as analysts incorporate the dual Phase 3 successes into their models and raise peak sales projections. The consensus now reflects expectations that Pharvaris can transition from a pre-revenue biotech to a commercial-stage company generating substantial HAE franchise revenue by the late 2020s, with some analysts forecasting €317-363 million in revenue by 2029.

Part 4: Technical Picture

Barchart Technical Opinion

The Barchart Technical Opinion for Pharvaris currently registers a 56% Buy signal, unchanged from last week's 56% Buy reading. However, this represents a dramatic improvement from one month ago, when the signal stood at just 8% Sell. This sharp reversal reflects the stock's strong recovery and positive momentum following the September CHAPTER-3 Phase 3 data release.

Timeframe Analysis

• Short-term (Hold): Neutral reading suggests near-term consolidation after the recent rally
• Medium-term (50% Buy): Moderate buy signal indicates building positive momentum in the intermediate timeframe
• Long-term (100% Buy): Strong buy signal reflects robust longer-term uptrend and structural strength

Trend Characteristics: The trend is characterized as Weak and Weakening, suggesting that while the directional bias remains positive, momentum may be losing steam in the near term as the stock digests recent gains.

Moving Average Analysis

Pharvaris is trading above all major moving averages, a bullish technical configuration. The stock at $33.99 sits above the 5-day MA ($33.94), 10-day MA ($33.79), 20-day MA ($32.11), 50-day MA ($33.33), 100-day MA ($33.98), and 200-day MA ($31.25). The tight clustering of the shorter-term averages around the current price suggests the stock is consolidating near recent highs, while the distance above the 200-day MA indicates a sustained uptrend over the longer term.

The technical setup heading into earnings is generally supportive but cautious. The stock's position above all moving averages provides a cushion of support, with the 200-day MA at $31.25 representing a key long-term floor roughly 8.8% below current levels. However, the "Weak" and "Weakening" trend characteristics, combined with the short-term Hold signal, suggest the stock may be vulnerable to profit-taking if results disappoint.

The 100-day MA at $33.98 is particularly notable, as the current price is trading just 0.03% below this level, making it a critical near-term support/resistance zone. A strong earnings report could propel the stock toward the recent high implied by the tight moving average structure, while a miss might trigger a test of the 20-day MA at $32.11. Given the historical earnings volatility averaging over 4% in either direction, traders should be prepared for a decisive break from the current consolidation pattern.